Wall Street’s top analyst upgrades/downgrades from earnings season: Amgen, Chevron, P&G, Netflix, Applied Materials, Datadog ...

The sizzle is the excitement about the hunt for the next big blockbuster, and the only one that anyone sees on the horizon is ...

Amgen (AMGN) stock is downgraded at Bernstein as the brokerage says 2026 may be a “waiting year” for the company. Read more here.

You can't hold back time, but scientists believe they may finally be able to slow down ageing. In a revolutionary new field, they are testing drugs to help people live healthier - for longer.

Coverage of a new PCSK9 trial makes bold claims about prevention and risk reduction. But how well do they hold up to scrutiny ...

Amgen has announced a deal with the US government that will lower the company’s prescription drug costs for US patients while reinforcing its commitment to US innovation.

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

Amgen reported early Phase 2 data suggesting patients kept weight off with less frequent dosing, a potential differentiator ...

Investing.com -- Bernstein cut its rating on Amgen Inc (NASDAQ:AMGN) to Market-Perform from Outperform, keeping its $335 price target, saying 2026 is likely to be a waiting year with limited catalysts ...

Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...

Q. My doctor prescribed rosuvastatin for high cholesterol. After taking it for six to nine months, I noticed that my cognitive function had slipped. I would not be able to find the word I was looking ...

The Trump-Vance administration took office on Jan. 20, 2025. The White House proceeded to dismantle the U.S. Agency for International Development, which funded LGBTQ and intersex rights organizations ...